Literature DB >> 19384325

Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?

Patrick H Nachman1.   

Abstract

Antineutrophil cytoplasmic antibody-associated vasculitides are usually treated with a combination of high-dose corticosteroids and cyclophosphamide therapy to induce remission, commonly followed by maintenance treatment with a less-toxic immunosuppressant. Azathioprine and methotrexate are both options for maintenance therapy, but whether one of these immunosuppressants is superior to the other is unclear.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19384325     DOI: 10.1038/nrneph.2009.52

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  9 in total

1.  Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis.

Authors:  Maria Koukoulaki; David R W Jayne
Journal:  Nephron Clin Pract       Date:  2005-11-10

2.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Kirsten De Groot; Niels Rasmussen; Paul A Bacon; Jan Willem Cohen Tervaert; Conleth Feighery; Gina Gregorini; Wolfgang L Gross; Raashid Luqmani; David R W Jayne
Journal:  Arthritis Rheum       Date:  2005-08

3.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

4.  Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.

Authors:  Susan L Hogan; Ronald J Falk; Hyunsook Chin; Jianwen Cai; Caroline E Jennette; J Charles Jennette; Patrick H Nachman
Journal:  Ann Intern Med       Date:  2005-11-01       Impact factor: 25.391

5.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

6.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

7.  Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.

Authors:  C Metzler; N Miehle; K Manger; C Iking-Konert; K de Groot; B Hellmich; W L Gross; E Reinhold-Keller
Journal:  Rheumatology (Oxford)       Date:  2007-05-22       Impact factor: 7.580

8.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

9.  Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.

Authors:  Christian Pagnoux; Susan L Hogan; Hyunsook Chin; J Charles Jennette; Ronald J Falk; Loïc Guillevin; Patrick H Nachman
Journal:  Arthritis Rheum       Date:  2008-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.